CD4+ T-cell-dependent tumour rejection in an immune-privileged environment requires macrophages

Immunology

Volumn 123, Issue 3, 2008, Pages 367-377

  Dace, Dru S ^a   Chen, Peter W ^a   Niederkorn, Jerry Y ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Immune privilege; Interferon ; Macrophages; T cells; Tumours

Indexed keywords

CLODRONIC ACID; FAS LIGAND; GAMMA INTERFERON; PERFORIN; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADENOVIRUS 5; ADOPTIVE TRANSFER; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL INFILTRATION; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; CYTOTOXICITY; DELAYED HYPERSENSITIVITY; EYE TUMOR; FLOW CYTOMETRY; GENE EXPRESSION; IMMUNE RESPONSE; IMMUNOCOMPETENCE; MACROPHAGE; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR IMMUNOLOGY; TUMOR REJECTION;

ADOPTIVE TRANSFER; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; EYE NEOPLASMS; HYPERSENSITIVITY, DELAYED; INTERFERON TYPE II; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, SCID; NEOPLASM TRANSPLANTATION;

EID: 38649095597     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2007.02700.x     Document Type: Article

References (54)

1. Whitsett CF, Stulting RD. The distribution of HLA antigens on human corneal tissue. Invest Ophthalmol Visual Sci 1984 25 : 519 24.
2. Streilein JW. Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat Rev Immunol 2003 3 : 879 89.
3. Niederkorn JY. See no evil, hear no evil, do no evil: the lessons of immune privilege. Nat Immunol 2006 7 : 354 9.
4. Niederkorn JY. Immune privilege in the anterior chamber of the eye. Crit Rev Immunol 2002 22 : 13 46.
5. Medawar PB. Immunity to homologous grafted skin. III. The fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol 1948 29 : 58 69.
6. Niederkorn JY, Wang S. Immunology of intraocular tumors. Ocular Immunol Inflammation 2005 13 : 105 10.
7. Knisely TL, Luckenbach MW, Fischer BJ, Niederkorn JY. Destructive and nondestructive patterns of immune rejection of syngeneic intraocular tumors. J Immunol 1987 138 : 4515 23.
8. Knisely TL, Niederkorn JY. Emergence of a dominant cytotoxic T lymphocyte antitumor effector from tumor-infiltrating cells in the anterior chamber of the eye. Cancer Immunol Immunother 1990 30 : 323 30.
9. Toes RE, Hoeben RC, van der Voort EI, Ressing ME, van der Eb AJ, Melief CJ, Offringa R. Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion. Proc Natl Acad Sci USA 1997 94 : 14660 5.
10. Schurmans LR, Diehl L, den Boer AT et al. Rejection of intraocular tumors by CD4(+) T cells without induction of phthisis. J Immunol 2001 167 : 5832 7.
11. Wang S, Boonman ZF, Li HC, He Y, Jager MJ, Toes RE, Niederkorn JY. Role of TRAIL and IFN-gamma in CD4+ T cell-dependent tumor rejection in the anterior chamber of the eye. J Immunol 2003 171 : 2789 96.
12. Dace DS, Chen PW, Alizadeh H, Niederkorn JY. Ocular immune privilege is circumvented by CD4+ T cells, leading to the rejection of intraocular tumors in an IFN-γ-dependent manner. J Leukoc Biol 2007 81 : 421 9.
13. Boonman ZF, Schurmans LR, van Rooijen N, Melief CJ, Toes RE, Jager MJ. Macrophages are vital in spontaneous intraocular tumor eradication. Invest Ophthalmol Visual Sci 2006 47 : 2959 65.
14. Whitworth PW, Pak CC, Esgro J, Kleinerman ES, Fidler IJ. Macrophages and cancer. Cancer Metastasis Rev 1990 8 : 319 51.
15. Munder M, Mallo M, Eichmann K, Modolell M. Murine macrophages secrete interferon gamma upon combined stimulation with interleukin (IL)-12 and IL-18: a novel pathway of autocrine macrophage activation. J Exp Med 1998 187 : 2103 8.
16. Homma S, Komita H, Sagawa Y, Ohno T, Toda G. Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12. Immunology 2005 115 : 451 61.
17. Toes RE, Offringa R, Blom RJ, Brandt RM, van der Eb AJ, Melief CJ, Kast WM. An adenovirus type 5 early region 1B-encoded CTL epitope-mediating tumor eradication by CTL clones is down-modulated by an activated ras oncogene. J Immunol 1995 154 : 3396 405.
18. Dace DS, Chen PW, Niederkorn JY. CD8+ T cells circumvent immune privilege in the eye and mediate intraocular tumor rejection by a TNF-α-dependent mechanism. J Immunol 2007 178 : 6115 22.
19. Schurmans LR, den Boer AT, Diehl L, van der Voort EI, Kast WM, Melief CJ, Toes RE, Jager MJ. Successful immunotherapy of an intraocular tumor in mice. Cancer Res 1999 59 : 5250 4.
20. Koo GC, Dumont FJ, Tutt M, Hackett J Jr., Kumar V. The NK-1.1(-) mouse: a model to study differentiation of murine NK cells. J Immunol 1986 137 : 3742 7.
21. Murphy WJ, Kumar V, Bennett M. Natural killer cells activated with interleukin 2 in vitro can be adoptively transferred and mediate hematopoietic histocompatibility-1 antigen-specific bone marrow rejection in vivo. Eur J Immunol 1990 20 : 1729 34.
22. Charley MR, Mikhael A, Bennett M, Gilliam JN, Sontheimer RD. Prevention of lethal, minor-determinate graft-host disease in mice by the in vivo administration of anti-asialo GM1. J Immunol 1983 131 : 2101 3.
23. Van Rooijen N. The liposome-mediated macrophage 'suicide' technique. J Immunol Meth 1989 124 : 1 6.
24. Greenberg PD, Kern DE, Cheever MA. Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells. J Exp Med 1985 161 : 1122 34.
25. Weber J, Rosenberg S. Modulation of murine tumor major histocompatibility antigens by cytokines in vivo and in vitro. Cancer Res 1988 48 : 5818 24.
26. Ellis TM, McKenzie RS, Simms PE, Helfrich BA, Fisher RI. Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma. J Immunol 1989 143 : 4282 6.
27. Niederkorn JY. The immunopathology of intraocular tumour rejection. Eye (London) 1991 5 : 186 92.
28. Niederkorn JY. Immunoregulation of intraocular tumours. Eye (London) 1997 11 : 249 54.
29. Ma D, Alizadeh H, Comerford SA, Gething MJ, Sambrook JF, Anand R, Niederkorn JY. Rejection of intraocular tumors from transgenic mice by tumor-infiltrating lymphocytes. Current Eye Res 1994 13 : 361 9.
30. Niederkorn JY, Meunier PC. Spontaneous immune rejection of intraocular tumors in mice. Invest Ophthalmol Visual Sci 1985 26 : 877 84.
31. Dailey MO, Pillemer E, Weissman IL. Protection against syngeneic lymphoma by a long-lived cytotoxic T-cell clone. Proc Natl Acad Sci USA 1982 79 : 5384 7.
32. Kast WM, Offringa R, Peters PJ, Voordouw AC, Meloen RH, van der Eb AJ, Melief CJ. Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes. Cell 1989 59 : 603 14.
33. Greenberg PD. Therapy of murine leukemia with cyclophosphamide and immune Lyt-2+ cells: cytolytic T cells can mediate eradication of disseminated leukemia. J Immunol 1986 136 : 1917 22.
34. Qin Z, Richter G, Schuler T, Ibe S, Cao X, Blankenstein T. B cells inhibit induction of T cell-dependent tumor immunity. Nat Med 1998 4 : 627 30.
35. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998 393 : 480 3.
36. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998 393 : 478 80.
37. Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 1998 393 : 474 8.
38. Pardoll DM, Topalian SL. The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol 1998 10 : 588 94.
39. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998 188 : 2357 68.
40. Mumberg D, Monach PA, Wanderling S, Philip M, Toledano AY, Schreiber RD, Schreiber H. CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc Natl Acad Sci USA 1999 96 : 8633 8.
41. Greenberg PD, Cheever MA, Fefer A. Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes. J Exp Med 1981 154 : 952 63.
42. Fujiwara H, Fukuzawa M, Yoshioka T, Nakajima H, Hamaoka T. The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity. J Immunol 1984 133 : 1671 6.
43. Corthay A, Skovseth DK, Lundin KU, Rosjo E, Omholt H, Hofgaard PO, Haraldsen G, Bogen B. Primary antitumor immune response mediated by CD4+ T cells. Immunity 2005 22 : 371 83.
44. Coughlin CM, Salhany KE, Gee MS et al. Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 1998 9 : 25 34.
45. Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-gamma. Annu Rev Immunol 1997 15 : 749 95.
46. Beatty G, Paterson Y. IFN-gamma-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4+ T cells requires tumor responsiveness to IFN-gamma. J Immunol 2001 166 : 2276 82.
47. Sgadari C, Angiolillo AL, Tosato G. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood 1996 87 : 3877 82.
48. Arenberg DA, Kunkel SL, Polverini PJ et al. Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med 1996 184 : 981 92.
49. Sgadari C, Farber JM, Angiolillo AL et al. Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo. Blood 1997 89 : 2635 43.
50. Belperio JA, Keane MP, Arenberg DA, Addison CL, Ehlert JE, Burdick MD, Strieter RM. CXC chemokines in angiogenesis. J Leukoc Biol 2000 68 : 1 8.
51. Strieter RM, Polverini PJ, Arenberg DA, Kunkel SL. The role of CXC chemokines as regulators of angiogenesis. Shock 1995 4 : 155 60.
52. Loetscher M, Gerber B, Loetscher P, Jones S, Piali L, Clark-Lewis I, Baggiolini M, Moser B. Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J Exp Med 1996 184 : 963 9.
53. Xie QW, Whisnant R, Nathan C. Promoter of the mouse gene encoding calcium-independent nitric oxide synthase confers inducibility by interferon gamma and bacterial lipopolysaccharide. J Exp Med 1993 177 : 1779 84.
54. Blankenstein T, Qin Z. The role of IFN-gamma in tumor transplantation immunity and inhibition of chemical carcinogenesis. Curr Opin Immunol 2003 15 : 148 54.